PDGFRA and cancer: Considering that ART compounds are currently clinically used drugs with favorable safety profiles, the results from this study will potentate their use in combination with clinically used PDGFRα inhibitors, leading to maximal therapeutic efficacy with minimal adverse effects in PDGFRα-positive cancer patients.